시장보고서
상품코드
1622422

단클론항체 요법 시장 규모, 점유율, 성장 분석 : 생산별, 공급원별, 치료법별, 투여별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Production (In Vitro, In Vivo), By Source (Human, Humanized), By Therapy, By Administration, By End User, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

단클론항체 요법 시장 규모는 2023년 1,540억 5,000만 달러로 평가되며, 2024년 1,653억 달러에서 2032년 2,904억 4,000만 달러로 예측 기간(2025-2032년) 동안 7.3%의 CAGR로 성장할 것으로 예상됩니다.

세계 단클론항체 요법 시장은 암, 자가면역질환, 심혈관질환 등 만성질환의 유병률 증가에 힘입어 높은 성장세를 보이고 있습니다. 이러한 질환의 치료에서 단클론항체의 효능은 그 채택을 크게 촉진하고 있습니다. 또한 인구 고령화와 생활습관병의 증가는 시장 확대에 박차를 가하고 있습니다. 기술 발전으로 고특이성 항체 생산능력이 강화되어 치료 효과가 향상되고 있습니다. 또한, 맞춤형 의료와 표적 치료의 중요성이 강조되면서 단클론항체 요법에 대한 수요가 증가하고 있으며, 향후 몇 년 동안 이 시장은 지속적으로 성장할 것으로 예상됩니다. 전반적으로, 이러한 추세는 헬스케어 분야에서 단클론항체의 미래가 유망하다는 것을 보여줍니다.

목차

소개

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 가정과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porters 분석

주요 시장 인사이트

  • 핵심성공요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

단클론항체 요법 시장 규모 : 생산별

  • 시장 개요
  • In vitro
  • In vivo

단클론항체 요법 시장 규모 : 공급원별

  • 시장 개요
  • 인간
  • 인간화
  • 키메라
  • 기타

단클론항체 요법 시장 규모 : 치료법별

  • 시장 개요
  • 자가면역질환 및 염증성 질환
  • 종양학
  • 혈액학
  • 안과
  • 기타

단클론항체 요법 시장 규모 : 투여별

  • 시장 개요
  • 정맥내
  • 피하
  • 기타

단클론항체 요법 시장 규모 : 최종사용자별

  • 시장 개요
  • 병원
  • 장기간병 시설
  • 기타
  • 단클론항체 요법 시장 규모
  • 북미(생산, 공급, 치료, 관리, 최종사용자)
    • 미국
    • 캐나다
  • 유럽(생산, 공급, 치료, 관리, 최종사용자)
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양(생산, 공급, 치료, 관리, 최종사용자)
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카(생산, 공급, 치료, 관리, 최종사용자)
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카(생산, 공급, 치료, 관리, 최종사용자)
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5개사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채용한 전략
  • 시장의 최근 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • 기업 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
  • 매출 전년비 비교(2022-2024)

주요 기업 개요

  • Zoetis Inc.(USA)
  • Merck & Co., Inc.(USA)
  • Elanco Animal Health Incorporated(USA)
  • Boehringer Ingelheim International GmbH(Germany)
  • Ceva Sante Animale(France)
  • Virbac(France)
  • Vetoquinol(France)
  • Bayer AG(Germany)
  • Novartis AG(Switzerland)
  • Eli Lilly and Company(USA)
  • Sanofi(France)
  • Intervet Inc.(Netherlands)
  • Alltech(Ireland)
  • Huvepharma(Bulgaria)
  • Kemin Industries(USA)
  • Novus International(USA)
  • Biomin Holding GmbH(Austria)
  • ADM Animal Nutrition(USA)
  • Adisseo(France)
  • DSM(Netherlands)

결론과 추천사항

ksm 25.01.15

Monoclonal Antibody Therapy Market size was valued at USD 154.05 Billion in 2023 and is poised to grow from USD 165.3 Billion in 2024 to USD 290.44 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global monoclonal antibody therapy market is witnessing robust growth, primarily driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. The effectiveness of monoclonal antibodies in treating these illnesses is significantly boosting their adoption. Furthermore, an aging population coupled with the increase in lifestyle-related diseases is fueling market expansion. Technological advancements have enhanced the production capabilities of highly specific antibodies, thereby improving therapeutic outcomes. Additionally, the growing emphasis on personalized medicine and targeted therapies is amplifying the demand for monoclonal antibody therapies, positioning this market for sustained growth in the coming years. Overall, these trends indicate a promising future for monoclonal antibodies in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segmental Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market is primarily driven by notable advancements in biotechnology and genetic engineering. These developments have been crucial in creating sophisticated monoclonal antibody therapies that exhibit enhanced specificity and efficacy while minimizing side effects. Innovative techniques, including genetic manipulation, enable researchers to tailor antibodies for particular targets, thereby maximizing their therapeutic effectiveness. As a result, these scientific breakthroughs have expanded the applications of monoclonal antibody therapies and significantly improved their success rates in treating various diseases. This continued evolution in biotechnology is essential for the growth and evolution of the monoclonal antibody therapy market.

Restraints in the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market faces several constraints primarily related to potential side effects and safety issues associated with these treatments. Patients may experience infusion-related reactions during administration, which can lead to discomfort and anxiety. Additionally, there is a risk of immunogenicity, where the patient's immune system reacts against the therapy itself, potentially reducing its effectiveness. Off-target effects may also occur, where the antibody interacts with unintended biological targets, leading to adverse outcomes. To mitigate these concerns, it is essential to implement rigorous safety monitoring, thorough risk assessments, and transparent communication regarding potential side effects, thereby upholding patient safety and trust in these therapies.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is witnessing a robust trend towards increasing adoption of personalized and targeted therapies. As healthcare shifts towards individualized treatment plans, monoclonal antibodies are at the forefront of this evolution, effectively treating conditions such as cancer, autoimmune disorders, and infectious diseases. The integration of companion diagnostics, genetic profiling, and biomarker identification enhances the development and prescription of these therapies, ensuring more precise treatments that optimize therapeutic efficacy and reduce adverse effects. This growing emphasis on personalized medicine is expected to drive substantial growth in the monoclonal antibody market, reflecting a transformative approach to disease management.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2025-2032)

  • Market Overview
  • In Vitro
  • In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2025-2032)

  • Market Overview
  • Human
  • Humanized
  • Chimeric
  • Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2025-2032)

  • Market Overview
  • Autoimmune And Inflammatory Disorders
  • Oncology
  • Hematology
  • Ophthalmology
  • Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2025-2032)

  • Market Overview
  • Intravenous
  • Subcutaneous
  • Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Long Term Care Facilities
  • Others
  • Global Monoclonal Antibody Therapy Market Size & CAGR (2025-2032)
  • North America (Production, Source, Therapy, Administration, End User)
    • US
    • Canada
  • Europe (Production, Source, Therapy, Administration, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Production, Source, Therapy, Administration, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Production, Source, Therapy, Administration, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Production, Source, Therapy, Administration, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Zoetis Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Elanco Animal Health Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim International GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ceva Sante Animale (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Virbac (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vetoquinol (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Intervet Inc. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alltech (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Huvepharma (Bulgaria)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kemin Industries (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novus International (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biomin Holding GmbH (Austria)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ADM Animal Nutrition (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adisseo (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DSM (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제